From killer to Chronic

MyoPatch is developing a unique proprietary, minimally invasive method for Stem Cell delivery.

Learn More

The MyoPatch Solution

  • MyoPatch is developing a unique, minimally invasive method for Stem Cell delivery based on Gel Patch in collaboration with a tech firm in the Weitzman Institute science park in Israel

  • Patent-protected low cost-of-goods treatment for heart failure

  • Delivering agnostic stem cells via minimally invasive means to the epicardium (needle through the chest, instead of open chest surgery)

  • Able to repeat treatment on outpatient basis, replacing currently invasive delivery methods (chiefly open-chest cardiac surgery)

  • In summary – turning a killer into a chronically manageable disease

Learn More

MyoPatch’s Competitive Advantage and what it’s offering to the industry

Our competitive advantage is based on MyoPatch being agnostic to any cell lines and therefore enable an early exit to participants. The MyoPatch offering is a win- win proposition :


  • Unique non-invasive injectable gel patch that is patent protected.
  • Low cost of delivery & manufacture
  • FDA 510(k), not a new drug, freedom to operate and unencumbered IP
  • Can be used by different clinicians & multiple diagnostic.
  • Simple day-case treatment, no open chest surgery
  • Change a diagnosis of slow death into a long-term manageable condition


Providing Stem Cell Companies

  • Rapidity to market, minimally invasive and superior results
  • High reimbursement/low CoGs
  • Large number of clinicians can use, not only cardiologists
  • New income for doctors and hospitals, rapid adoption

Founders & Management

Dr. Jeremy Stone MD MBA

Co Founder - Chief medical Officer

Eytan Lombroso

Co Founder - Head of business affairs

Dr. Asher Holzer PhD

Chairman, Chief development officer, Founder

Mr. Arnon Gal


Explore Investing in MyoPatch

Lern More